Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA
Marme F, Hanusch C, Furlanetto J, Denkert C, Link T, Untch M, Blohmer JU, Jackisch C, Reinisch M, Rhiem KE, Schneeweiss A, Solbach C, Schoellhorn L, Fasching P, Rey J, Loibl S (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S443-S444
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2021.08.480
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Mannheim
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Gießen und Marburg (UKGM)
Germany (DE)
Technische Universität Dresden
Germany (DE)
HELIOS Kliniken
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Gießen und Marburg (UKGM)
Germany (DE)
Technische Universität Dresden
Germany (DE)
HELIOS Kliniken
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
How to cite
APA:
Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M.,... Loibl, S. (2021). Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. In ANNALS OF ONCOLOGY (pp. S443-S444). AMSTERDAM: ELSEVIER.
MLA:
Marme, F., et al. "Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S443-S444.
BibTeX: Download